
Boehringer and Cue partner to advance autoimmune disease candidate in deal worth $357m
Boehringer Ingelheim and Cue Biopharma have announced a partnership worth $357m to develop and commercialise Cue’s pre-clinical B cell depletion therapy for autoimmune diseases. The multi-year collaboration and licence agreement will see the companies use …